MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

In today's session, these stocks are experiencing unusual volume.

Discover the stocks with unexpected trading volume in today's session on the US markets.

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by disastrous trial results. Meanwhile, macro tension builds with a potential U.S. government shutdown and Friday’s key jobs report looming.

U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to 46,316.07. These are the top stocks that gained the attention of retail traders and investors throughout the day.

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.

MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug.

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive.

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

The deal is being discussed ahead of key data from MoonLake in patients with a skin disease.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.